Teva accelerates cost reduction program
10 October 2013 | By Teva Pharmaceutical Industries Ltd
$2.0 billion in annual cost savings by the end of 2017 including $1.0 billion by the end of 2014...
List view / Grid view
10 October 2013 | By Teva Pharmaceutical Industries Ltd
$2.0 billion in annual cost savings by the end of 2017 including $1.0 billion by the end of 2014...
4 October 2013 | By Teva Pharmaceutical Industries Ltd
Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis...
3 October 2013 | By Teva Pharmaceutical Industries Ltd
Teva believes unpredictable differences between a proposed generic product and COPAXONE® could lead to immunogenic effects in patients...
3 October 2013 | By Teva Pharmaceutical Industries Ltd
“To our knowledge, glatiramer acetate is the only treatment for multiple sclerosis that has been prospectively studied for nearly two decades..."
1 October 2013 | By Teva Pharmaceutical Industries Ltd
"This Phase III sub-study was pre-planned to explore the ability of laquinimod to act on mechanisms leading to irreversible brain tissue damage..."
27 September 2013 | By Teva Pharmaceutical Industries Ltd
Series of events throughout Congress to shed light on new data and evolving MS landscape...
23 September 2013 | By Teva
The Court has upheld the validity of Teva’s patent. Teva anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect® until Teva’s patent expires in 2017.
17 September 2013 | By Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) approved TREANDA (bendamustine HCI) Injection, a new formulation of the currently approved TREANDA (bendamustine HCI) for Injection.
16 September 2013 | By Cancer Research Technology Ltd.
Cancer Research Technology and Teva Pharmaceutical have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells...
30 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL®)...
12 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA and Perrigo Company announced the launch of the generic equivalent to Temodar® (temozolomide)...
8 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim)...
17 June 2013 | By Teva Pharmaceutical Industries Ltd.
Teva has entered into a definitive agreement to acquire MicroDose Therapeutx...
3 June 2013 | By Teva Pharmaceutical Industries Ltd
Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU for the reduction of CIN...
30 May 2013 | By Teva Pharmaceutical Industries Ltd.
"We are pleased that the FDA has accepted for review our sNDA..."